Back to mobile site

RBC Capital Reiterates Outperform Rating on Ideaya Biosciences (IDYA)

September 24, 2024 6:14 AM EDT Send to a Friend
RBC Capital analyst Gregory Renza reiterated an Outperform rating and $61.00 price target on Ideaya Biosciences (NASDAQ: IDYA).The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login